BioAtla, Inc. (BCAB)
BCAB Stock Price Chart
Explore BioAtla, Inc. interactive price chart. Choose custom timeframes to analyze BCAB price movements and trends.
BCAB Company Profile
Discover essential business fundamentals and corporate details for BioAtla, Inc. (BCAB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Dec 2020
Employees
61.00
Website
https://www.bioatla.comCEO
Jay Short
Description
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
BCAB Financial Timeline
Browse a chronological timeline of BioAtla, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$8.50.
Earnings released on 15 May 2026
EPS came in at -$6.18 surpassing the estimated -$10.00 by +38.20%.
Stock split effective on 6 Apr 2026
Shares were split 1 : 50 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Mar 2026
EPS came in at -$8.00 surpassing the estimated -$12.00 by +33.33%, while revenue for the quarter reached $2.00m , beating expectations by +185.71%.
Earnings released on 13 Nov 2025
EPS came in at -$0.27 surpassing the estimated -$0.31 by +12.90%.
Earnings released on 7 Aug 2025
EPS came in at -$0.31 falling short of the estimated -$0.29 by -6.90%.
Earnings released on 6 May 2025
EPS came in at -$0.29 falling short of the estimated -$0.28 by -3.57%.
Earnings released on 27 Mar 2025
EPS came in at -$0.32 surpassing the estimated -$0.40 by +20.00%.
Earnings released on 7 Nov 2024
EPS came in at -$0.22 surpassing the estimated -$0.34 by +35.29%, while revenue for the quarter reached $11.00m .
Earnings released on 8 Aug 2024
EPS came in at -$0.44 surpassing the estimated -$0.45 by +2.22%.
Earnings released on 14 May 2024
EPS came in at -$0.48 surpassing the estimated -$0.57 by +15.79%.
Earnings released on 26 Mar 2024
EPS came in at -$0.56 surpassing the estimated -$0.79 by +29.11%.
Earnings released on 7 Nov 2023
EPS came in at -$0.70 surpassing the estimated -$0.77 by +9.09%.
Earnings released on 1 Aug 2023
EPS came in at -$0.75 falling short of the estimated -$0.64 by -17.19%.
Earnings released on 11 May 2023
EPS came in at -$0.58 surpassing the estimated -$0.66 by +12.12%.
Earnings released on 23 Mar 2023
EPS came in at -$0.63 surpassing the estimated -$0.74 by +14.86%.
Earnings released on 4 Nov 2022
EPS came in at -$0.69 surpassing the estimated -$0.77 by +10.39%.
Earnings released on 9 Aug 2022
EPS came in at -$0.77 falling short of the estimated -$0.70 by -10.00%.
Earnings released on 5 May 2022
EPS came in at -$0.65 surpassing the estimated -$0.69 by +5.80%.
Earnings released on 1 Mar 2022
EPS came in at -$0.63 falling short of the estimated -$0.58 by -8.60%, while revenue for the quarter reached $250.00k , missing expectations by -94.57%.
Earnings released on 15 Nov 2021
EPS came in at -$0.68 falling short of the estimated -$0.64 by -5.57%.
Earnings released on 13 Aug 2021
EPS came in at -$0.90 falling short of the estimated -$0.56 by -60.71%, while revenue for the quarter reached $250.00k , beating expectations by +2.85%.
BCAB Stock Performance
Access detailed BCAB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
